First Trust Advisors LP reduced its stake in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 34.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 999,166 shares of the biopharmaceutical company’s stock after selling 516,029 shares during the period. First Trust Advisors LP owned 1.73% of Ultragenyx Pharmaceutical worth $42,744,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in RARE. Vanguard Group Inc. grew its position in shares of Ultragenyx Pharmaceutical by 2.3% during the second quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock worth $317,874,000 after acquiring an additional 112,101 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Ultragenyx Pharmaceutical by 31.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock worth $292,858,000 after acquiring an additional 1,110,316 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of Ultragenyx Pharmaceutical by 19.6% during the second quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock worth $50,628,000 after acquiring an additional 130,561 shares during the last quarter. Northern Trust Corp grew its position in shares of Ultragenyx Pharmaceutical by 5.0% during the second quarter. Northern Trust Corp now owns 691,110 shares of the biopharmaceutical company’s stock worth $43,886,000 after acquiring an additional 32,812 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 5.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 318,418 shares of the biopharmaceutical company’s stock worth $20,220,000 after acquiring an additional 17,415 shares during the last quarter.

In other news, CEO Emil D. Kakkis bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was purchased at an average price of $43.63 per share, with a total value of $218,150.00. Following the purchase, the chief executive officer now owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.80% of the company’s stock.

RARE has been the topic of a number of research reports. Piper Jaffray Companies set a $75.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday. ValuEngine lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Leerink Swann reiterated a “positive” rating and issued a $85.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. Finally, Wedbush reiterated a “buy” rating and issued a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $71.92.

NASDAQ:RARE traded up $0.06 during midday trading on Tuesday, reaching $37.56. The stock had a trading volume of 14,187 shares, compared to its average volume of 482,758. The firm has a fifty day simple moving average of $41.88 and a two-hundred day simple moving average of $54.22. Ultragenyx Pharmaceutical Inc has a 12-month low of $36.73 and a 12-month high of $74.50. The company has a quick ratio of 6.64, a current ratio of 6.79 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.25 billion, a P/E ratio of -5.06 and a beta of 2.15.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the consensus estimate of ($1.71) by ($0.25). Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The firm had revenue of $25.80 million during the quarter, compared to analyst estimates of $28.88 million. During the same period in the previous year, the firm posted ($1.74) EPS. The company’s revenue for the quarter was up 119.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc will post -7.28 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Recommended Story: What are Closed-End Mutual Funds?

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.